Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
100.25M | 91.65M | 83.62M | 72.58M | 62.71M | 57.30M | Gross Profit |
57.29M | 55.13M | 45.77M | 39.15M | 33.90M | 30.01M | EBIT |
-682.02K | -8.33M | -4.07M | -4.13M | -651.38K | -940.98K | EBITDA |
1.44M | -2.33M | 698.39K | 820.83K | 3.57M | 4.31M | Net Income Common Stockholders |
-6.00M | -12.24M | -8.00M | -4.44M | -1.19M | -1.12M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
12.84M | 16.18M | 11.96M | 15.64M | 21.11M | 30.17M | Total Assets |
63.92M | 69.80M | 62.49M | 58.09M | 56.17M | 61.69M | Total Debt |
18.54M | 6.72M | 23.51M | 12.01M | 8.91M | 15.53M | Net Debt |
5.70M | -9.46M | 11.55M | -3.63M | -12.20M | -14.64M | Total Liabilities |
34.02M | 24.78M | 40.09M | 30.31M | 24.01M | 27.86M | Stockholders Equity |
29.90M | 45.02M | 22.40M | 27.79M | 32.16M | 33.84M |
Cash Flow | Free Cash Flow | ||||
809.32K | -7.72M | -10.29M | -6.93M | -1.43M | 3.00M | Operating Cash Flow |
2.32M | -6.33M | -3.88M | 1.86M | 2.71M | 5.19M | Investing Cash Flow |
-4.52M | -5.34M | -6.41M | -8.47M | -4.37M | -1.83M | Financing Cash Flow |
6.91M | 16.68M | 6.61M | 2.09M | -6.80M | 18.87M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
53 Neutral | AU$136.15M | ― | -15.86% | ― | 12.93% | 62.47% | |
50 Neutral | AU$54.78M | ― | -8.08% | ― | -5.62% | -225.71% | |
50 Neutral | AU$68.93M | ― | -51.08% | ― | 10.22% | -2.94% | |
48 Neutral | AU$151.79M | ― | -58.61% | ― | ― | -74.88% | |
44 Neutral | AU$116.69M | ― | -35.20% | ― | 4.68% | -155.42% | |
42 Neutral | AU$139.65M | ― | -52.37% | ― | 471.29% | -4.58% |
SomnoMed Limited’s latest quarterly cash flow report reveals a net cash inflow from operating activities amounting to $848,000 for the current quarter, indicating a positive operational performance. However, the company experienced a net cash outflow from investing activities of $932,000, reflecting ongoing investments in property, plant, and equipment, as well as intellectual property. The overall cash position improved by $18,498,000, suggesting robust financial management despite the challenges in the investment domain.
SomnoMed Limited, a leader in oral appliance treatment solutions for sleep-related breathing disorders, has assessed the potential impact of new reciprocal tariffs announced by the USA on its operations. With the Philippines as its primary manufacturing location, the company plans to absorb the immediate costs of these tariffs to ensure uninterrupted patient care. SomnoMed maintains its FY25 revenue guidance of approximately $105 million and an EBITDA of between $7 million to $9 million, demonstrating its commitment to stakeholders despite the evolving tariff situation.